The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).
Daniel A. Goldstein
No relevant relationships to disclose
Qiushi Chen
No relevant relationships to disclose
David H. Howard
No relevant relationships to disclose
Joseph Lipscomb
No relevant relationships to disclose
Turgay Ayer
No relevant relationships to disclose
Bassel F. El-Rayes
Research Funding - Roche
Christopher Flowers
Consultant or Advisory Role - Genentech/Roche (U)